Designed to yield insights about therapeutic mechanisms of action and/or characteristics of a responder population, the new artificial intelligence (AI)-based offering enables clinical trial sponsors to utilize Vida's biomarker generation services, according to the vendor. Vida offers more than 50 biomarkers, including new chest and vascular imaging biomarkers.

Available for both prospective clinical trials and respective datasets, the new chest imaging biomarkers include airway biomarkers for mucus plug scoring, bronchiectasis scoring, and total airway count, according to the vendor. Other new functional chest imaging biomarkers include respiratory airflow dynamics and ventilation defect probability mapping. Vida has also incorporated coronary artery calcium score as a new vascular biomarker.

Vida Ventures adds $825M to portfolio
Vida Ventures announced the closing of Vida Ventures III on $825 million in an oversubscribed fund. The company now has over $1.7 billion of...